ArticleUrology case reports2026
Primary bladder diffuse large B-cell lymphoma causing unilateral ureterovesical junction obstruction: A case report.
Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary bladder diffuse large B-cell lymphoma is a rare extranodal malignancy that often mimics urothelial carcinoma. We report a 65-year-old male with flank pain and hematuria found to have a bladder mass extending to the ureterovesical junction with hydroureteronephrosis; urine cytology was repeatedly negative. Cystoscopic biopsy confirmed DLBCL, with no marrow involvement. Transurethral resection plus R-CHOP chemotherapy produced complete metabolic response on FDG-PET/CT, with stable residual uptake later deemed post-treatment change (Deauville 3). This case highlights ureteral obstruction as an unusual presentation and serial PET/CT as valuable for distinguishing residual lymphoma from fibrosis after therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.